MAY 18, 2021 7:00 AM PDT

Hitting the Achilles' Heel of Cancers with Confidence - Robust Validation of Neoantigens

Sponsored by: Agilent
Speaker

Abstract
Date:  May 18, 2021
Time: 7:00am PDT, 10:00am EDT
 
Proteins encoded by mutant genes in cancers can be processed and presented on tumor cell surface by human leukocyte antigen (HLA) molecules, and such mutant peptides are called Neoantigens. Neoantigens are naturally existing tumor markers. To identify the exact sequence of a neoantigen with high confidence is the key to the success of many cancer immunotherapeutics. In this presentation, we will discuss advancements and difficulties of prediction-dependent and prediction-independent neoantigen identification strategies. We will review the latest development of technologies for neoantigen identification and introduce our unique neoantigen detection and quantification pipeline based on a triple quadrupole mass spectrometer.
 
 
Learning Objectives:
  • Gain familiarity of the advancements and difficulties of prediction-dependent and prediction-independent neoantigen identification strategies.
  • Understand the latest development of technologies for neoantigen identification
 
 
For Research Use Only. Not for use in diagnostic procedures.
 
 
Webinars will be available for unlimited on-demand viewing after live event.

 

 


Show Resources
Show Resources
Connect with us